A Study to Evaluate Mosunetuzumab in Participants With Systemic Lupus Erythematosus With or Without Active Lupus Nephritis

Sponsor
Hoffmann-La Roche
Study ID
NCT07598396
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Mosunetuzumab — DRUG
    Participants will receive SC mosunetuzumab.

Study Details

This study will assess how mosunetuzumab works in people who have systemic lupus erythematosus (SLE) who may or may not also have active lupus nephritis (LN).

Key Dates

First listed
May 20, 2026
Start date
May 25, 2026
Status verified
Aug 2026
Primary completion
Feb 28, 2028
Completion
Aug 31, 2028

Study Design

Enrollment
30 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Mosunetuzumab
    Participants will receive mosunetuzumab by subcutaneous (SC) injection.

Primary Outcome Measure

Proportion of participants who have achieved remission by Week 76 [ Time Frame: Up to Week 76 ]

Central Contacts

  • Reference Study ID Number: GA45799 https://forpatients.roche.com/ No attachments to email below.
    888-662-6728 (U.S. Only)
    [email protected]
  • Fastest response: use the inquiry form. https://www.gene.com/contact-us/submit-medical-inquiry

Find similar trials

Nationwide
Lupus (SLE) trialsRheumatology trialsAutoimmune disease trials

Related Studies